A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
| Autor: | Matcheri S. Keshavan, L. Fredrik Jarskog, Cameron S. Carter, Margaret A. Peykamian, Michael F. Green, Larry J. Seidman, Alan Breier, Martin T. Lowy, John G. Csernansky, Jeffrey A. Lieberman, Joshua T. Kantrowitz, Donald C. Goff, Stephen R. Marder, Richard S.E. Keefe, M. Patricia Ball, Robert P. McMahon, Joseph P. Horrigan, Robert W. Buchanan, Marc Laurelle, Paul Maruff, Richard Grove |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
education.field_of_study medicine.drug_class medicine.medical_treatment Population Antagonist Placebo Receptor antagonist Gastroenterology Psychiatry and Mental health Internal medicine medicine Clinical endpoint Histamine H3 receptor Antipsychotic Psychiatry education Adverse effect Psychology Biological Psychiatry |
| Zdroj: | Schizophrenia Research. 164:136-142 |
| ISSN: | 0920-9964 |
| Popis: | This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect